| Symbol | PRFX |
|---|---|
| Name | PAINREFORM LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 65 YIGAL ALON ST., TEL AVIV, 6744316, Israel |
| Telephone | +972 37177051 |
| Fax | — |
| — | |
| Website | https://www.painreform.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001801834 |
| Description | PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. Additional info from NASDAQ: Additional info from NASDAQ: |
PRF Technologies’ DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
Read moreNew Form EFFECT - PRF Technologies Ltd. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 9999999995-26-002155 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - PRF Technologies Ltd. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001178913-26-003368 <b>Size:</b> 252 KB
Read morePRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Read moreNew Form SCHEDULE 13G/A - PRF Technologies Ltd. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001104659-26-076350 <b>Size:</b> 23 KB
Read moreNew Form SCHEDULE 13G/A - PRF Technologies Ltd. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001178913-26-003227 <b>Size:</b> 7 KB
Read morePRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
Read morePRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
Read moreNew Form 424B3 - PRF Technologies Ltd. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001178913-26-002809 <b>Size:</b> 243 KB
Read moreNew Form F-1 - PRF Technologies Ltd. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001178913-26-002645 <b>Size:</b> 520 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05773846 | A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical … | Phase3 | Bunion | Completed | 2023-03-13 | 2024-08-30 | ClinicalTrials.gov |
| NCT02784327 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of PR… | Phase2 | Post Operative Pain | Unknown | 2016-08-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01681966 | A Single-dose Open-Label Study to Assess the Safety and Preliminary Efficacy of… | Phase2 | Post Operative Pain | Completed | 2012-09-01 | 2016-05-04 | ClinicalTrials.gov |
| NCT00883194 | A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunt… | Phase1 | Pain | Completed | 2010-10-01 | 2011-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PRF110 | Other | Phase PHASE2 | Post Operative Pain | UNKNOWN | NCT02784327 |
| PRF110- oily solution (Ropivacaine) | Other | Phase PHASE2 | Post Operative Pain | COMPLETED | NCT01681966 |
| Ropivacaine | Other | Phase PHASE3 | Bunion | COMPLETED | NCT05773846 |
| PRF110 | DRUG | Phase PHASE2 | Post Operative Pain | UNKNOWN | NCT02784327 |
| PRF110- oily solution (Ropivacaine) | DRUG | Phase PHASE2 | Post Operative Pain | COMPLETED | NCT01681966 |
| PRF-110 | DRUG | Phase PHASE1 | Pain | COMPLETED | NCT00883194 |
| Ropivacaine | DRUG | Phase PHASE3 | Bunion | COMPLETED | NCT05773846 |
| Placebo | DRUG | Phase PHASE1 | Pain | COMPLETED | NCT00883194 |
| PRF-108 | DRUG | Phase PHASE1 | Pain | COMPLETED | NCT00883194 |